<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3619">
  <stage>Registered</stage>
  <submitdate>15/08/2012</submitdate>
  <approvaldate>15/08/2012</approvaldate>
  <nctid>NCT01666977</nctid>
  <trial_identification>
    <studytitle>Phase 1b/2 Trial of AMG386 With Pemetrexed and Carboplatin in Non-Small Cell Lung Cancer</studytitle>
    <scientifictitle>A Phase 1b/2 Trial of AMG 386 in Combination With Pemetrexed and Carboplatin as First Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2011-001111-31</secondaryid>
    <secondaryid>20101128</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Non Small Cell Lung Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Mesothelioma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Non small cell</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lung - Small cell</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - AMG 386
Treatment: drugs - AMG 386
Treatment: drugs - AMG 386 Placebo
Treatment: drugs - Pemetrexed
Treatment: drugs - Carboplatin

Experimental: Arm A - Arm A: AMG 386 placebo IV QW, pemetrexed 500 mg/m2 IV Q3W, carboplatin AUC 6 IV Q3W, for up to 6 cycles

Experimental: Arm B - Arm B: AMG 386 15 mg/kg IV QW, pemetrexed 500 mg/m2 IV Q3W, carboplatin AUC 6 IV Q3W, for up to 6 cycles

Experimental: Arm C - Arm C: AMG 386 30 mg/kg IV QW, pemetrexed 500 mg/m2 IV Q3W, carboplatin AUC 6 IV Q3W, for up to 6 cycles


Treatment: drugs: AMG 386
15mg/kg

Treatment: drugs: AMG 386
30 mg/kg

Treatment: drugs: AMG 386 Placebo
AMG 386 Placebo

Treatment: drugs: Pemetrexed
Pemetrexed 500 mg/m2

Treatment: drugs: Carboplatin
Carboplatin AUC 6

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Progression Free Survival - Subjects will be evaluated for progression free survival.</outcome>
      <timepoint>Incidence of adverse events and clinical laboratory abnormalities defined as a DLT</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Histologically confirmed, unresectable stage IV non-squamous non small cell lung
             cancer (NSCLC)

          -  Radiographically evaluable disease (measurable or non-measurable) per RECIST 1.1 with
             modifications

          -  Adequate hematological, renal, and hepatic function, normal coagulation profile,
             calculated CrCL = 45 mL/min

          -  Other criteria may apply</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>95</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Any prior chemotherapy or targeted therapy for non-squamous NSCLC

          -  Subjects with adenosquamous histology or any histology subtype containing greater than
             10% squamous cells

          -  Subjects with an epidermal growth factor receptor (EGFR) mutation sensitive to
             treatment with a tyrosine kinase inhibitor (TKI)

          -  Subjects with known anaplastic lymphoma kinase (EML4-ALK) translocations

          -  History or presence of central nervous system metastases

          -  Central (chest) radiation therapy within 28 days prior to enrollment/randomization,
             radiation therapy to any other site(s) within 14 days prior to
             enrollment/randomization

          -  History of pulmonary hemorrhage or gross hemoptysis within 6 months

          -  History of arterial or venous thromboembolism within 12 months

          -  History of clinically significant bleeding within 6 months

          -  Clinically significant cardiovascular disease within 12 months

          -  Other criteria may apply</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1/Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>36</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/11/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,VIC</recruitmentstate>
    <hospital>Research Site - Camperdown</hospital>
    <hospital>Research Site - Kogarah</hospital>
    <hospital>Research Site - Randwick</hospital>
    <hospital>Research Site - Tweed Heads</hospital>
    <hospital>Research Site - Herston</hospital>
    <hospital>Research Site - Bentleigh East</hospital>
    <hospital>Research Site - Heidelberg</hospital>
    <postcode>2050 - Camperdown</postcode>
    <postcode>2217 - Kogarah</postcode>
    <postcode>2031 - Randwick</postcode>
    <postcode>2485 - Tweed Heads</postcode>
    <postcode>4029 - Herston</postcode>
    <postcode>3165 - Bentleigh East</postcode>
    <postcode>3084 - Heidelberg</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arkansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Hampshire</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Dakota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Bruxelles</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Heraklion</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Larissa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Patra</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Thessaloniki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Andalucía</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Aragón</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Amgen</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this phase 1b/2 study is to estimate the treatment effect of study drug
      measuring progression free survival.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01666977</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>MD</name>
      <address>Amgen</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>